Roche, Prothena Form $600M Parkinson's Partnership

Law360, New York (December 12, 2013, 1:45 PM EST) -- Biotech companies Roche Holding Ltd. and Prothena Corp. PLC will partner up to the tune of $600 million to develop and sell treatments for Parkinson's disease, the companies said Wednesday.

Roche will harness Prothena's research and make payments to the company for meeting milestones in developing marketable antibodies for proteins that degrade neurons, causing Parkinson's. Roche's initial payment will be $45 million, followed by $380 million for achieving first commercial sales, plus another $175 million for meeting sales benchmarks. The deal centers around Prothena's test drug...
To view the full article, register now.